Debevoise Advises Actavis in Divesting Aptalis Pharmaceutical Technologies

13 February 2015

The New York and Paris offices of Debevoise & Plimpton LLP are advising Actavis plc (“Actavis”) in its definitive agreements to divest the business currently known as Aptalis Pharmaceutical Technologies (“PharmaTech”) — a pharmaceutical outsourcing and R&D business within Actavis' subsidiary Aptalis operating in the United States, Canada and Europe (where the transaction is, in certain jurisdictions, still subject to local regulations, discussions and clearances). No other Aptalis businesses or products are included in the transaction. No financial terms were disclosed.

Actavis, headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world. The company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

The Debevoise team is led by partner Andrew L. Bab and includes partners Pierre Clermontel, Jeffrey P. Cunard, Gary M. Friedman and Jonathan F. Lewis, international counsel Eric Berengier, and associates Roxane Castro, Jennifer L. Chu, Simone S. Hicks, Michael Layfield, Charles-Philippe Letellier, Anjali Salooja and Max Shaul.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. The firm’s commercially savvy lawyers regularly lead strategic transactions and complex disputes for world-class clients.